Healthcare / Medical DevicesNYSE
$47.98
-0.33 (-0.68%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.4B · quality 76.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$71.3B
P/E
20.1x
↓EV/EBITDA
15.9x
↑ROE
12.0%
↑Gross Margin
69.0%
↑Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+5.0%
FCF CAGR
+10.4%
FCF margin
17.0%
FCF / Net income
1.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.07B · net income $2.90B · FCF $3.40B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $20.07B | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B | $10.73B | $9.82B | $9.05B | $8.39B | $7.48B | $7.38B | $7.14B | $7.25B | $7.62B | $7.81B | $8.19B | $8.05B | $8.36B |
| Net Income | $2.90B | $2.90B | $1.85B | $1.59B | $698.0M | $1.04B | $-82.0M | $4.70B | $1.67B | $104.0M | $347.0M | $-239.0M | $-119.0M | $-121.0M | $-4.07B | $441.0M | $-1.06B | $-1.02B | $-2.04B | $-495.0M |
| EBITDA | $5.10B | $5.10B | $3.86B | $3.45B | $2.75B | $2.29B | $1.04B | $2.53B | $2.40B | $2.13B | $1.26B | $486.0M | $424.0M | $809.0M | $-3.19B | $1.62B | $160.0M | $-60.0M | $-641.0M | $904.0M |
| EPS | 1.94 | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 | -0.08 | 3.33 | 1.19 | 0.08 | 0.25 | -0.18 | -0.09 | -0.09 | -2.89 | 0.29 | -0.70 | -0.68 | -1.36 | -0.33 |
| Gross Margin | 69.0% | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% | 65.0% | 71.0% | 71.4% | 71.3% | 71.1% | 70.9% | 70.1% | 69.6% | 67.6% | 65.1% | 66.7% | 68.5% | 69.3% | 72.0% |
| Operating Margin | 19.8% | 19.8% | 17.9% | 17.0% | 16.0% | 10.1% | -0.8% | 14.1% | 15.3% | 14.2% | 5.3% | -3.8% | -4.1% | 1.7% | -53.4% | 11.9% | -8.4% | -10.9% | -18.7% | -0.2% |
| Net Margin | 14.4% | 14.4% | 11.1% | 11.2% | 5.5% | 8.8% | -0.8% | 43.8% | 17.0% | 1.1% | 4.1% | -3.2% | -1.6% | -1.7% | -56.1% | 5.8% | -13.6% | -12.5% | -25.3% | -5.9% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.47 | 0.47 | 0.49 | 0.49 | 0.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.90 | 1.90 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $3.40B | $3.40B | $2.37B | $1.70B | $914.0M | $1.32B | $1.13B | $1.38B | $-6.0M | $1.11B | $806.0M | $444.0M | $1.01B | $865.0M | $1.05B | $704.0M | $53.0M | $523.0M | $854.0M | $571.0M |
| Returns | ||||||||||||||||||||
| ROE | 12.0% | 12.0% | 8.5% | 8.3% | 4.0% | 6.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Valuation | ||||||||||||||||||||
| P/E | 20.08 | 20.08 | 72.55 | 54.36 | 102.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 15.91 | 15.91 | 37.63 | 27.20 | 27.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.96 | 2.96 | 6.19 | 4.41 | 3.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 19.9% | 19.9% | 17.6% | 12.3% | — | 19.9% | -7.7% | 9.3% | 8.6% | 7.9% | 12.2% | 1.3% | 3.3% | -1.5% | -4.9% | -2.4% | -4.7% | 1.7% | -3.7% | — |
| EPS Growth | 55.2% | 55.2% | 16.8% | 137.8% | — | 962.5% | -102.4% | 179.8% | 1387.5% | -68.0% | 238.9% | -100.0% | 0.0% | 96.9% | -1096.6% | 141.4% | -2.9% | 50.0% | -312.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
30.0%
EPS terminal req.
$4.26
Spread vs growth
25.2%
5Y implied EPS CAGR
21.6%
EPS terminal req.
$5.15
Spread vs growth
33.6%
10Y implied EPS CAGR
15.6%
EPS terminal req.
$8.30
Spread vs growth
39.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-54.4%
Start / end P/E
84.2x → 24.7x
EPS bridge
1.25 → 1.94
Residual
-39.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.